Trevena (TRVN) AI Stock Analysis

• Market Cap: $9.59K
• Dividend Yield: N/A
• Average Volume (3M): 1.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 863,788
• 10 Day Avg. Volume: 1,032
• 30 Day Avg. Volume: 1,103
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.74
• Price to Sales (P/S): 4.27
• P/FCF Ratio: -0.40
• Enterprise Value/Market Cap: 2.82K
• Enterprise Value/Revenue: 49.38
• Enterprise Value/Gross Profit: -18.64
• Enterprise Value/Ebitda: -1.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

Trevena's overall stock score is low, driven by severe financial challenges including negative equity and persistent operational losses. Technical analysis indicates a bearish trend, while valuation metrics further underscore the stock's unattractiveness. Recent corporate events, such as leadership changes and delisting, contribute additional risk and uncertainty.

Positive Factors

Product Portfolio

OLINVYK's FDA approval for acute pain management provides a strong foundation for Trevena's product portfolio, supporting long-term revenue potential in the pain management sector.

Strategic Partnerships

Strategic partnerships and licensing agreements enhance Trevena's ability to expand its market reach and leverage external expertise, contributing to sustainable growth.

Leadership Stability

The appointment of Katrine Sutton as CFO, with her extensive industry experience, is expected to strengthen financial management and strategic decision-making, supporting long-term stability.

Negative Factors

Financial Health

Trevena's negative equity and ongoing losses highlight severe financial instability, posing significant long-term risks to its operational sustainability and ability to invest in growth.

Revenue Decline

The sharp decline in revenue growth indicates weakening market demand or competitive pressures, challenging Trevena's ability to maintain its market position and grow its business.

Cash Flow Issues

Deteriorating cash flow generation limits Trevena's financial flexibility, impacting its capacity to fund operations, invest in R&D, and manage debt, threatening long-term viability.

Trevena Business Overview & Revenue Model

Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

How the Company Makes Money

Trevena makes money primarily through the commercialization of its pharmaceutical products, particularly OLINVYK, which generates revenue from sales to hospitals and healthcare facilities. The company's revenue model is driven by product sales, licensing agreements, and potential milestone payments from strategic partnerships. Trevena also explores collaborations with other pharmaceutical companies to expand the reach and development of its drug candidates, which may involve upfront payments, milestone achievements, and royalty agreements. As a biopharmaceutical entity, Trevena's financial success is highly dependent on the market adoption of its approved drugs and the successful development and approval of its pipeline candidates.

Trevena Financial Statement Overview

Summary

Trevena's financial health is concerning with declining revenues, persistent losses, and negative equity. The company faces significant challenges in achieving profitability and sustaining operations, necessitating strategic interventions to improve financial stability and performance.

Income Statement

Trevena's income statement shows significant challenges. The Gross Profit Margin is negative for the TTM (Trailing-Twelve-Months) at -265.63%, indicating cost inefficiencies. The Net Profit Margin is also negative at -6219.74%, reflecting substantial losses. Revenue has decreased sharply compared to the previous year, with a Revenue Growth Rate of -82.50%, suggesting declining sales. The EBIT and EBITDA margins are negative, at -5870.75% and -7172.57% respectively, highlighting ongoing operational losses.

Balance Sheet

The balance sheet presents a precarious financial position with negative Stockholders' Equity in the TTM, resulting in a negative Equity Ratio. The Debt-to-Equity Ratio is not meaningful due to negative equity. Return on Equity (ROE) is also not calculable. These figures indicate potential solvency issues and high financial risk.

Cash Flow

Trevena's cash flows are under stress, with a negative Free Cash Flow Growth Rate of -18.01%, showing deteriorating cash generation. The Operating Cash Flow to Net Income Ratio is 0.80, suggesting cash losses align with net losses. The Free Cash Flow to Net Income Ratio at 0.80 further underscores ongoing cash burn issues.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	547.00K	3.13M	-418.00K	567.00K	3.07M	31.00K
Gross Profit	-1.45M	1.46M	-3.44M	-387.00K	2.89M	-77.00K
EBITDA	-26.20M	-34.95M	-52.03M	-51.08M	-28.66M	-25.61M
Net Income	-34.02M	-40.29M	-53.67M	-51.59M	-29.37M	-24.87M
Balance Sheet
Total Assets	19.19M	40.60M	48.68M	80.12M	127.74M	46.99M
Cash, Cash Equivalents and Short-Term Investments	13.46M	32.98M	38.32M	66.92M	109.40M	35.80M
Total Debt	37.56M	36.24M	19.77M	7.10M	7.80M	13.46M
Total Liabilities	42.50M	48.26M	33.08M	15.49M	23.67M	16.92M
Stockholders Equity	-23.31M	-7.66M	15.60M	64.63M	104.07M	30.08M
Cash Flow
Free Cash Flow	-27.11M	-33.08M	-51.51M	-50.21M	-21.42M	-23.67M
Operating Cash Flow	-27.09M	-33.03M	-51.48M	-50.20M	-21.39M	-23.67M
Investing Cash Flow	-21.00K	-41.00K	18.00K	-16.00K	3.47M	25.58M
Financing Cash Flow	5.70M	26.31M	23.50M	7.73M	95.02M	-2.50M

Trevena Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRVN, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, above the 50-day MA of <0.01, and below the 200-day MA of 0.57, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRVN.

Trevena Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DRMA	44 Neutral	$2.26M	-0.11	-203.36%	―	―	90.53%
GRI	42 Neutral	$3.32M	-0.02	-397.84%	―	―	98.22%
SCNI	39 Underperform	$818.36K	-0.08	―	―	178.82%	-4121.10%
TRVN	31 Underperform	$9.59K	―	145.94%	―	―	―